Latest Information Update: 18 Jan 2017
At a glance
- Originator Pfizer
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic fatty liver disease
Most Recent Events
- 06 Jan 2017 Pfizer suspends participant recruitment in a phase I trial in Non-alcoholic fatty liver disease (In volunteers) in USA (PO) (NCT02974374)
- 01 Oct 2016 Phase-I clinical trials in Non-alcoholic fatty liver disease (In volunteers) in USA (PO) (NCT02974374)